"Example:\nSentence: \"However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans.\"\nEntities: glucocorticoids, psychostimulants\nTriplets:\n(glucocorticoids, no interaction, psychostimulants)\n\nExample:\nSentence: \"The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.\"\nEntities: HUMIRA, anakinra\nTriplets:\n(anakinra, no interaction, HUMIRA)\n\nExample:\nSentence: \"Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.\"\nEntities: Uricosuric Agents, oxipurinol, uricosuric agents\nTriplets:\n(Uricosuric Agents, no interaction, oxipurinol)\n(Uricosuric Agents, no interaction, uricosuric agents)\n(Uricosuric Agents, no interaction, oxipurinol)\n(oxipurinol, no interaction, uricosuric agents)\n(oxipurinol, no interaction, oxipurinol)\n(uricosuric agents, mechanism, oxipurinol)\n\nExample:\nSentence: \"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.\"\nEntities: Aspirin, Uricosuric Agents, phenylbutazone, probenecid, sulfinpyrazone\nTriplets:\n(Uricosuric Agents, no interaction, Aspirin)\n(Uricosuric Agents, no interaction, probenecid)\n(Uricosuric Agents, no interaction, sulfinpyrazone)\n(Uricosuric Agents, no interaction, phenylbutazone)\n(Aspirin, effect, probenecid)\n(Aspirin, effect, sulfinpyrazone)\n(Aspirin, effect, phenylbutazone)\n(probenecid, no interaction, sulfinpyrazone)\n(probenecid, no interaction, phenylbutazone)\n(sulfinpyrazone, no interaction, phenylbutazone)\n\nExample:\nSentence: \"- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.\"\nEntities: Bezalip, Bezalip retard, insulin, sulphonylureas\nTriplets:\n(sulphonylureas, no interaction, insulin)\n(sulphonylureas, effect, Bezalip)\n(sulphonylureas, effect, Bezalip retard)\n(insulin, effect, Bezalip)\n(insulin, effect, Bezalip retard)\n(Bezalip, no interaction, Bezalip retard)\n\nExample:\nSentence: \"Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.\"\nEntities: VIRACEPT, nelfinavir\nTriplets:\n(VIRACEPT, no interaction, nelfinavir)\n\nExample:\nSentence: \"When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.\"\nEntities: SUSTIVA, indinavir\nTriplets:\n(indinavir, mechanism, SUSTIVA)\n(indinavir, no interaction, indinavir)\n(indinavir, no interaction, indinavir)\n(SUSTIVA, no interaction, indinavir)\n(SUSTIVA, no interaction, indinavir)\n(indinavir, no interaction, indinavir)\n\nExample:\nSentence: \"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;\"\nEntities: TRACRIUM, enflurane\nTriplets:\n(TRACRIUM, effect, enflurane)\n\nExample:\nSentence: \"Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.\"\nEntities: Antiminth, Pyrantel, piperazine, pyrantel\nTriplets:\n(Pyrantel, no interaction, Antiminth)\n(Pyrantel, no interaction, piperazine)\n(Pyrantel, no interaction, pyrantel)\n(Pyrantel, no interaction, piperazine)\n(Antiminth, no interaction, piperazine)\n(Antiminth, no interaction, pyrantel)\n(Antiminth, no interaction, piperazine)\n(piperazine, effect, pyrantel)\n(piperazine, no interaction, piperazine)\n(pyrantel, no interaction, piperazine)\n\nExample:\nSentence: \"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).\"\nEntities: Antabuse, Isocarboxazid, disulfiram\nTriplets:\n(Isocarboxazid, advise, Antabuse)\n(Isocarboxazid, advise, disulfiram)\n(Antabuse, no interaction, disulfiram)\n\nExample:\nSentence: \"Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.\"\nEntities: LEVSIN, amantadine, antihistamines, antimuscarinics, haloperidol, monoamine oxidase (MAO) inhibitors, phenothiazines, tricyclic antidepressants\nTriplets:\n(LEVSIN, effect, antimuscarinics)\n(LEVSIN, effect, amantadine)\n(LEVSIN, effect, haloperidol)\n(LEVSIN, effect, phenothiazines)\n(LEVSIN, effect, monoamine oxidase (MAO) inhibitors)\n(LEVSIN, effect, tricyclic antidepressants)\n(LEVSIN, effect, antihistamines)\n(antimuscarinics, no interaction, amantadine)\n(antimuscarinics, no interaction, haloperidol)\n(antimuscarinics, no interaction, phenothiazines)\n(antimuscarinics, no interaction, monoamine oxidase (MAO) inhibitors)\n(antimuscarinics, no interaction, tricyclic antidepressants)\n(antimuscarinics, no interaction, antihistamines)\n(amantadine, no interaction, haloperidol)\n(amantadine, no interaction, phenothiazines)\n(amantadine, no interaction, monoamine oxidase (MAO) inhibitors)\n(amantadine, no interaction, tricyclic antidepressants)\n(amantadine, no interaction, antihistamines)\n(haloperidol, no interaction, phenothiazines)\n(haloperidol, no interaction, monoamine oxidase (MAO) inhibitors)\n(haloperidol, no interaction, tricyclic antidepressants)\n(haloperidol, no interaction, antihistamines)\n(phenothiazines, no interaction, monoamine oxidase (MAO) inhibitors)\n(phenothiazines, no interaction, tricyclic antidepressants)\n(phenothiazines, no interaction, antihistamines)\n(monoamine oxidase (MAO) inhibitors, no interaction, tricyclic antidepressants)\n(monoamine oxidase (MAO) inhibitors, no interaction, antihistamines)\n(tricyclic antidepressants, no interaction, antihistamines)\n\nExample:\nSentence: \"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.\"\nEntities: VIOXX, Warfarin, warfarin\nTriplets:\n(Warfarin, no interaction, VIOXX)\n(Warfarin, no interaction, warfarin)\n(VIOXX, advise, warfarin)\n\nExample:\nSentence: \"The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.\"\nEntities: dirithromycin, terfenadine\nTriplets:\n(terfenadine, no interaction, terfenadine)\n(terfenadine, no interaction, terfenadine)\n(terfenadine, no interaction, dirithromycin)\n(terfenadine, no interaction, terfenadine)\n(terfenadine, no interaction, dirithromycin)\n(terfenadine, no interaction, dirithromycin)\n\nExample:\nSentence: \"Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.\"\nEntities: Cyclosporine, L-arginine, cyclosporin\nTriplets:\n(Cyclosporine, no interaction, L-arginine)\n(Cyclosporine, no interaction, cyclosporin)\n(L-arginine, effect, cyclosporin)\n\nExample:\nSentence: \"Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.\"\nEntities: Acetaminophen, theophylline\nTriplets:\n(Acetaminophen, mechanism, theophylline)\n\nExample:\nSentence: \"Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.\"\nEntities: ouabain, palytoxin\nTriplets:\n(ouabain, no interaction, palytoxin)\n\nExample:\nSentence: \"On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.\"\nEntities: amiodarone, digitalis\nTriplets:\n(amiodarone, advise, digitalis)\n\nExample:\nSentence: \"In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.\"\nEntities: dirithromycin, theophylline\nTriplets:\n(dirithromycin, no interaction, theophylline)\n(dirithromycin, no interaction, theophylline)\n(dirithromycin, no interaction, theophylline)\n(theophylline, no interaction, theophylline)\n(theophylline, no interaction, theophylline)\n(theophylline, no interaction, theophylline)\n\nExample:\nSentence: \"Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.\"\nEntities: Antacids, aluminum hydroxide, antacid, antacids, fosinopril, fosinoprilat, magnesium hydroxide, simethicone\nTriplets:\n(Antacids, no interaction, antacid)\n(Antacids, no interaction, aluminum hydroxide)\n(Antacids, no interaction, magnesium hydroxide)\n(Antacids, no interaction, simethicone)\n(Antacids, no interaction, fosinopril)\n(Antacids, no interaction, fosinoprilat)\n(Antacids, no interaction, fosinopril)\n(Antacids, no interaction, antacids)\n(Antacids, no interaction, fosinopril)\n(antacid, no interaction, aluminum hydroxide)\n(antacid, no interaction, magnesium hydroxide)\n(antacid, no interaction, simethicone)\n(antacid, mechanism, fosinopril)\n(antacid, no interaction, fosinoprilat)\n(antacid, no interaction, fosinopril)\n(antacid, no interaction, antacids)\n(antacid, no interaction, fosinopril)\n(aluminum hydroxide, no interaction, magnesium hydroxide)\n(aluminum hydroxide, no interaction, simethicone)\n(aluminum hydroxide, mechanism, fosinopril)\n(aluminum hydroxide, no interaction, fosinoprilat)\n(aluminum hydroxide, no interaction, fosinopril)\n(aluminum hydroxide, no interaction, antacids)\n(aluminum hydroxide, no interaction, fosinopril)\n(magnesium hydroxide, no interaction, simethicone)\n(magnesium hydroxide, mechanism, fosinopril)\n(magnesium hydroxide, no interaction, fosinoprilat)\n(magnesium hydroxide, no interaction, fosinopril)\n(magnesium hydroxide, no interaction, antacids)\n(magnesium hydroxide, no interaction, fosinopril)\n(simethicone, mechanism, fosinopril)\n(simethicone, no interaction, fosinoprilat)\n(simethicone, no interaction, fosinopril)\n(simethicone, no interaction, antacids)\n(simethicone, no interaction, fosinopril)\n(fosinopril, no interaction, fosinoprilat)\n(fosinopril, no interaction, fosinopril)\n(fosinopril, no interaction, antacids)\n(fosinopril, no interaction, fosinopril)\n(fosinoprilat, no interaction, fosinopril)\n(fosinoprilat, no interaction, antacids)\n(fosinoprilat, no interaction, fosinopril)\n(fosinopril, no interaction, antacids)\n(fosinopril, no interaction, fosinopril)\n(antacids, mechanism, fosinopril)\n\nExample:\nSentence: \"Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.\"\nEntities: CELEBREX, lithium\nTriplets:\n(lithium, advise, CELEBREX)\n"